Stock Market Reviews

AEMD (Aethlon Medical, Inc.) News

Get the latest news, insights, and market updates on AEMD (Aethlon Medical, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million
  Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 595,897 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 1,042,820 shares of common stock, in a private placement priced a
  Dec 5, 2025 - $AEMD
• Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs
  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, announced today the 20 November 2025 publication of a pre-clinical study entitled "Increased mannosylation of extracellular vesicles in Long COVID plasma provides a potential therapeutic target for Galanthus nivalis agglutinin (GNA) affinity resin" in the pre-print online archive bioRxiv: https://www.biorxiv.org/cgi/content/short/2025.11.21.
  Dec 2, 2025 - $AEMD
• AEMD: Can Increased Treatments Extend, Further Improve Positive Patient Responses?
  By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Cohort 2 recruitment has begun following positive data from Cohort 1 Aethlon Medical (NASDAQ:AEMD) announced FY 2Q (quarter ended September 30, 2025) results and provided a business update this week. The company’s primary focus is on researching lead asset, the Hemopurifier® therapeutic blood filtration system, as a potential treatment in
  Nov 14, 2025 - $AEMD
• Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update
  Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2025, and provided an update on recent developments.
  Nov 12, 2025 - $AEMD
• Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025
  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2025, at 4:15 p.m. ET on Wednesday, November 12, 2025.
  Nov 7, 2025 - $AEMD
• AEMD: Early Oncology Trial Data Looks Promising
  By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Cohort 1 preliminary data looks promising regarding Hemopurifier’s potential as an oncology treatment but it is early in the study Aethlon Medical (NASDAQ:AEMD) is conducting a basket oncology trial to study the impact of the Hemopurifier® therapeutic blood filtration system as a potential treatment in patients with various solid tumors
  Oct 21, 2025 - $AEMD
• AEMD: Oncology Trial Advances as Early Data Looks Promising
  By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Cohort 1 preliminary data looks promising regarding Hemopurifier’s potential as an oncology treatment but it is early in the study Aethlon Medical (NASDAQ:AEMD) is conducting a basket oncology trial to study the impact of the Hemopurifier® therapeutic blood filtration system as a potential treatment in patients with various solid tumors
  Oct 10, 2025 - $AEMD
• Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial
  Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) today provided observations on the preliminary changes in extracellular vesicle (EV), microRNA and lymphocyte counts in the first patient cohort in its ongoing oncology clinical trial in Australia. The study is a safety, feasibility, and dose-finding trial evaluating the company's Hemopurifier (HP) in patients with cancer not responding to anti-PD-1 therapy.
  Oct 7, 2025 - $AEMD
• Aethlon Medical announces pricing of $4.5M common stock, warrant offering
  Aethlon Medical (AEMD) announced the pricing of a public offering of an aggregate of 5M shares of its common stock and warrants to purchase up to 5M shares of common stock at a combined public offering price of 90c per share and accompanying warrant. The warrants will have an exercise price of 90c per share, will be exercisable immediately upon issuance and will expire on the fifth anniversary of the original issuance date. The closing of the offering is expected to occur on or about September 5
  Sep 5, 2025 - $AEMD
• Aethlon Medical Announces Pricing of $4.5 Million Public Offering
  Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 5,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.90 per share (or pre-funded warrant) and accompanying warrant.
  Sep 4, 2025 - $AEMD